Does MOTS-c burn visceral fat? What the mouse studies found, and why people try it for weight loss anyway

MOTS-c is best known online as a longevity and “exercise in a vial” peptide, but it also sits in weight-loss conversations next to semaglutide and tirzepatide, usually with one claim attached: that it targets the deep belly fat around the organs, called visceral fat. The US Anti-Doping Agency notes that many websites and social media influencers promote MOTS-c as an injectable weight loss and body building peptide drug. This page looks only at the weight-loss side. It asks what the mouse metabolism studies actually measured about fat, what little exists in people, how MOTS-c compares with the approved weight-loss drugs, and why people are trying it anyway. For the full overview of the peptide, see The Treatment Report’s MOTS-c guide.

Does MOTS-c burn visceral fat?

There is no evidence that MOTS-c burns visceral fat in people, because no completed human study has measured it. In mice fed a high-fat diet, MOTS-c injections curbed weight gain, and the founding research group reported that it caused a significant reduction in HFD-induced visceral fat and hepatic steatosis (fatty liver). Those mice were prevented from gaining fat on a rich diet; that is not the same as an adult losing existing belly fat.

What is MOTS-c, and why is it in the weight-loss conversation?

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, first described in 2015. Its weight-loss reputation comes from that founding Cell Metabolism paper, whose title says it promotes metabolic homeostasis and reduces obesity and insulin resistance, a claim tested in mice. In the lab it acts mainly on skeletal muscle and switches on AMPK, the cell’s energy sensor, which pushes cells toward using fuel rather than storing it (Lee et al., 2015). Our sister site covers the metabolic research on MOTS-c in depth.

Why are people trying MOTS-c for weight loss?

People reach for MOTS-c for weight loss for reasons that differ from why they take a GLP-1 drug. The common goals, as the marketing and community posts frame them:

• Fat loss without appetite suppression. In the founding high-fat-diet experiment, the lower weight was not attributed to food intake, as caloric intake was identical between the groups. That makes MOTS-c attractive to people who dislike the nausea and lost appetite of GLP-1 drugs.
• An add-on to a GLP-1. Community posts describe MOTS-c inside wider routines that include GLP peptides, fasting and cardio, rather than as a standalone weight-loss drug (see the community section below).
• Keeping muscle while losing weight. A 2021 mouse study reported that MOTS-c prevented the HFD-induced drop in total and gastrocnemius muscle mass relative to body weight in mice on a three-week high-fat diet, and lowered myostatin, a protein that limits muscle growth, in mice treated for eight weeks. Muscle loss is a real concern on GLP-1 drugs, which our page on preventing muscle loss on a GLP-1 covers.
• The “exercise in a vial” pitch. Exercise raises the body’s own MOTS-c in muscle (Reynolds et al., 2021), which marketing turns around into the idea that taking it mimics training.

What did the MOTS-c mouse studies find about fat?

The evidence level is animal and cell studies. Every fat outcome below was measured in mice, mostly in animals eating a high-fat diet, and most studies prevented fat gain rather than removing fat that was already there.

Two patterns stand out. First, the fat results are about mice on a fattening diet being protected from gaining fat, and the short three-day study saw no weight change at all. Second, the mechanism is still open: the founding authors themselves wrote that it is unclear whether the visceral-fat reduction reflects less fat building or more fat breakdown (Lee, Kim and Cohen, 2016).

Is MOTS-c a fat burner or an appetite suppressant?

In mice it looked more like an energy-use signal than an appetite suppressant. In the founding high-fat-diet experiment, calorie intake was identical between groups while treated mice produced more heat, which the authors linked to higher energy expenditure (Lee et al., 2015). GLP-1 drugs work largely by reducing appetite. Whether MOTS-c raises energy use in people has not been measured.

What do human studies show about MOTS-c and body fat?

Human evidence on MOTS-c and weight is observational, plus one small trial of a related drug. None of it shows that taking MOTS-c reduces body fat.

• Blood levels point in both directions. A 2018 study found circulating MOTS-c levels were decreased in obese male children and adolescents. A 2025 Mayo Clinic study of 22 lean and 32 obese adults found the reverse: levels were significantly higher in obese compared to lean individuals, and in 10 people followed for six months after bariatric surgery, levels stayed unchanged despite large BMI drops. The authors suggest MOTS-c may represent a compensatory metabolic response in obesity. That cuts against the idea that adults with obesity simply lack MOTS-c.
• An analog trial showed a trend, not a result. CB4211 is a drug developed from MOTS-c, not MOTS-c itself. In 20 adults with obesity and fatty liver treated for four weeks, its sponsor reported a trend towards lower body weight, with statistical significance claimed for liver enzymes and glucose but not for weight. Liver fat fell by a similar amount in both groups: 5.03 percentage points on CB4211 and 4.88 on placebo. That is a company press release, not a peer-reviewed paper.
• The only registered MOTS-c treatment trial does not measure weight. A placebo-controlled phase 2a trial in an estimated 120 adults with prediabetes and overweight or obesity began in February 2026. Its primary outcomes are insulin sensitivity at 12 weeks and adverse events, and its listed secondary outcomes are blood sugar measures and antibodies, not body weight or fat (ClinicalTrials.gov, NCT07505745). It has no results yet.

Does MOTS-c work for weight loss?

Nobody knows yet, and the one trial now running is not designed to answer it. The mouse results are real and consistent: on a high-fat diet, MOTS-c treated mice gained less fat. But no human study has given MOTS-c and measured weight, total fat or visceral fat as an outcome. Anyone using it for weight loss is relying on mouse data.

How does MOTS-c compare with GLP-1 drugs for weight loss?

On evidence, MOTS-c is at the bottom of the ladder and the approved GLP-1 drugs are at the top. The table compares the human weight result for each; the full ranking, including retatrutide and 5-Amino-1MQ, is in our guide to peptides for weight loss, and the 5-Amino-1MQ safety record is in 5-Amino-1MQ side effects and evidence.

The head-to-head comparison of the two approved drugs is in semaglutide vs tirzepatide.

Can you stack MOTS-c with a GLP-1?

People do, but no study has tested MOTS-c together with a GLP-1 drug, so any benefit or risk of the combination is unknown. The appeal is easy to see: pair a drug that cuts appetite with one pitched as raising energy use and protecting muscle. The muscle half of that pitch rests on the mouse myostatin study (Kumagai et al., 2021), and that paper also reported that in people, plasma MOTS-c was inversely correlated with myostatin levels, an association rather than a treatment effect. Stacking also makes it impossible to tell which compound caused a side effect or a result.

What are the side effects of MOTS-c for weight loss?

MOTS-c’s human safety record is largely blank. USADA states that it is unknown under what conditions (if any) it is safe to use MOTS-c because there are no completed human clinical trials, and that there is no data on long-term use. Among people who say they buy it online, USADA lists reported effects including increased heart rate or heart palpitations, injection site irritation, insomnia, immune reactions and fever. In the four-week CB4211 analog trial, the only adverse events in more than 10% of treated people were mild to moderate injection-site reactions (CohBar, August 10, 2021). Our sister site’s MOTS-c side effects guide sets out the full record. Anyone with diabetes or on glucose-lowering drugs has extra reason to talk to a clinician, since MOTS-c’s main measured effect in mice was on insulin sensitivity.

How long does MOTS-c take to work for weight loss?

There is no human answer, because no study has tracked weight on MOTS-c in people. In mice, fat-gain differences were reported after about ten days to eight weeks of daily treatment, while a three-day study found no weight change (Reynolds et al., 2021; Lee et al., 2015; Kim et al., 2019). Mouse timelines do not translate directly to people.

What does MOTS-c cost for weight loss?

There is no reference price, because there is no approved MOTS-c product for an insurer or pharmacy to price. What a buyer pays is set by whoever sells it, and because no study defines how long to use it for weight loss, the total cost is open-ended. That contrasts with the approved drugs, whose costs depend on insurance and maker programs, covered in our guide to GLP-1 cost without insurance. Whatever the price, the outcome being paid for has been measured in mice.

What is the community saying about MOTS-c for weight loss?

Our Community Insights summary for MOTS-c analyzed 19 public posts on X from July 16 to 19, 2026. These are anecdotes, not evidence, and none of the recurring themes was a report of measured fat loss.

• Part of a bigger routine. Posters describe running MOTS-c alongside NAD+, GHK-Cu, GLP peptides and pre-workout, often with fasting and cardio, and experimenting with timing around fasts and training.
• Energy, not the scale. The most common framing is MOTS-c as a mitochondrial energy peptide. Some report noticeable improvements, and one poster who expected to dismiss it revisited his verdict after a month of daily use.
• Pairing with SS-31. Users debate whether to run it with SS-31, another mitochondria-targeted peptide, together or in sequence, with no agreement.
• Hype skepticism. Others describe it as part of a hype cycle in which people chase each new peptide.

On Reddit, threads we track include one in r/Biohackers titled “PSA: be careful with MOTS-c” and a “MOTS-c review so far” in r/Peptides.

Set against the research, the weight-loss story runs ahead of the data in a specific way. Online it is sold as a fat-loss peptide, but the people using it mostly talk about energy and stacks, and the trial now running measures blood sugar, not weight. The visceral-fat claim traces back to mice protected from a high-fat diet.

The bottom line

MOTS-c reduced diet-induced fat gain, including visceral and liver fat, in mice, and it did so without changing how much they ate. That is a real finding and a reason to study it. It is not evidence that MOTS-c burns visceral fat in people, and the one human trial underway is not measuring weight. If weight loss is the goal, the compounds with human results are the approved GLP-1 drugs; MOTS-c is an experiment layered on top.

Status: Not FDA-approved; sold by some telehealth providers as a compounded prescription. An FDA advisory committee reportedly voted in July 2026 to recommend allowing pharmacies to compound it; nothing has changed yet. What these status terms mean.

Educational information only, not medical advice. Every efficacy and safety statement on this page is sourced to the peer-reviewed literature, trial registries, a company trial announcement or the US Anti-Doping Agency, linked above; the community summary reflects public posts on X analyzed in July 2026. Updated October 12, 2026. This page is drafted with AI assistance and fact-checked against the cited primary sources before publication.